Lymph node ratio as an independent predictor of survival in pancreatic adenocarcinoma: Insights from a retrospective cohort study
American Journal of Clinical Pathology · 04.06.2026 · 165 (6)
DOI: 10.1093/ajcp/aqag037 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 05.06.2026. Verfasst von Ana María Colino-Gallardo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Pathology, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Lymph Node Ratio, Lymph Nodes. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Objectives
We evaluated the prognostic impact of lymph node yield (LNY) and lymph node ratio (LNR) on disease-free survival (DFS) and overall survival (OS) after resection for pancreatic adenocarcinoma.
Methods
Using a retrospective cohort of 214 patients who had undergone surgical resection between 2000 and 2022), LNY was dichotomized at the median (≤13 vs >13 nodes). The LNR was categorized as 0, 0.01 to 0.20, and greater than 0.20. Survival was analyzed using Kaplan-Meier/log rank and multivariable Cox regression; node-negative category (N0) sensitivity analyses were performed.
Results
The LNY was not significantly associated with differences in DFS (14 vs 15 months; P = .72) or OS (18 vs 26 months; P = .27), although N0 patients showed a trend toward longer OS with higher LNY (22 vs 36 months; P = .087). The LNR statistically significantly separated DFS (19 vs 10 vs 12 months; P = .003) and OS (28 vs 20 vs 18 months; P = .045). In Cox models, an LNY below 13 was protective for DFS (hazard ratio [HR], 0.633; P = .03) and borderline for OS (HR, 0.705; P = .07). Compared with an LNR of 0, an LNR of 0.01 to 0.20 or greater than 0.20 independently predicted recurrence (HR, 1.921; P = .006 and HR, 1.745; P = .02); for OS, only an LNR greater than 0.20 remained significant (HR, 1.752; P = .01). A higher LNR was associated with lymphovascular/perineural invasion and progression.
Conclusions
Lymph node ratio is an independent prognostic marker after resection that predicts recurrence and—when above 0.20—mortality, whereas LNY mainly reflects staging adequacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Pathology, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.
- Grupo de Investigación en Tumores Digestivos, Hospital Clínico San Carlos, IdiSSC, Madrid, Spain.
- Department of Surgical Pathology, Hospital Clínico San Carlos, Madrid, Spain.
- Department of Legal Medicine, Psychiatry and Surgical Pathology, Complutense University of Madrid, Madrid, Spain.
- Department of Surgical Pathology, Clínica Universidad de Navarra, Madrid, Spain.
- Department of General and Digestive Surgery, Hospital Clínico San Carlos, Madrid, Spain.
ORCID-Profile: Ana María Colino-Gallardo
Zitieren
APA
Colino-Gallardo, A. M., Fernández-Aceñero, M. J., Vega-González, J., De La Torre-Serrano, M., Díaz-Suárez, M. P., Ortega-Medina, L., Diez-Valladares, L. I., & Martínez-Useros, J. (2026). Lymph node ratio as an independent predictor of survival in pancreatic adenocarcinoma: Insights from a retrospective cohort study. American Journal of Clinical Pathology, 165(6). https://doi.org/10.1093/ajcp/aqag037
Vancouver
Colino-Gallardo AM, Fernández-Aceñero MJ, Vega-González J, De La Torre-Serrano M, Díaz-Suárez MP, Ortega-Medina L, et al. Lymph node ratio as an independent predictor of survival in pancreatic adenocarcinoma: Insights from a retrospective cohort study. American Journal of Clinical Pathology. 2026;165(6). doi:10.1093/ajcp/aqag037
BibTeX
@article{ColinoGallardo2026,
author = {Colino-Gallardo, Ana María and Fernández-Aceñero, María Jesús and Vega-González, Jesús and De La Torre-Serrano, Montserrat and Díaz-Suárez, María Pilar and Ortega-Medina, Luis and Diez-Valladares, Luis Ignacio and Martínez-Useros, Javier},
title = {Lymph node ratio as an independent predictor of survival in pancreatic adenocarcinoma: Insights from a retrospective cohort study},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {165},
number = {6},
doi = {10.1093/ajcp/aqag037}
}
EUVIMED